Abstract
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Barriers to effective CAR-T cell therapy include severe life-threatening toxicities, modest anti-tumor activity, antigen escape, restricted trafficking, and limited tumor infiltration. In addition, the host and tumor microenvironment interactions with CAR-T cells critically alter CAR-T cell function. Furthermore, a complex workforce is required to develop and implement these treatments. In order to overcome these significant challenges, innovative strategies and approaches to engineer more powerful CAR-T cells with improved anti-tumor activity and decreased toxicity are necessary. In this review, we discuss recent innovations in CAR-T cell engineering to improve clinical efficacy in both hematological malignancy and solid tumors and strategies to overcome limitations of CAR-T cell therapy in both hematological malignancy and solid tumors.
Keywords
Chimeric antigen receptorMalignancyLymphomaTumor microenvironmentMedicineCancer researchCell therapyT cellLeukemiaCancerImmunologyCellImmune systemBiologyInternal medicineTumor cells
MeSH Terms
AnimalsHematologic NeoplasmsHumansImmunotherapyAdoptiveNeoplasmsReceptorsChimeric AntigenT-LymphocytesTumor Microenvironment
Affiliated Institutions
Related Publications
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Chimeric antigen receptor-modified T cells with specificity for CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL). It remains to be established whet...
Tumor Rejection After Direct Costimulation of CD8 <sup>+</sup> T Cells by B7-Transfected Melanoma Cells
A variety of tumors are potentially immunogenic but do not stimulate an effective anti-tumor immune response in vivo. Tumors may be capable of delivering antigen-specific signal...
Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells
Immunotherapy has shown great promise in the fight against cancer, as evidenced by the clinical efficacy of chimeric antigen receptor T cells in hematologic malignancies and che...
<i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates
Abstract The programmed death-1 (PD-1) receptor serves as an immunologic checkpoint, limiting bystander tissue damage and preventing the development of autoimmunity during infla...
Targeting Tumor Microenvironment for Cancer Therapy
Cancer development is highly associated to the physiological state of the tumor microenvironment (TME). Despite the existing heterogeneity of tumors from the same or from differ...
Publication Info
- Year
- 2021
- Type
- review
- Volume
- 11
- Issue
- 4
- Pages
- 69-69
- Citations
- 2373
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
2373
OpenAlex
70
Influential
Cite This
Robert C. Sterner,
Rosalie M. Sterner
(2021).
CAR-T cell therapy: current limitations and potential strategies.
Blood Cancer Journal
, 11
(4)
, 69-69.
https://doi.org/10.1038/s41408-021-00459-7
Identifiers
- DOI
- 10.1038/s41408-021-00459-7
- PMID
- 33824268
- PMCID
- PMC8024391